102 Avenue Gaston Roussel
About BiophytisBiophytis Is A Biotechnology Company Created In 2006. It Develops First-In-Class Drugs To Treat Degenerative Illnesses Associated With Aging For Which There Is Currently No Treatment. Its Two Most Advanced Programmes Relate To Sarcopenia (Loss Of Muscle Functionality) And Age-Related Macular Degeneration (ARMD).
CEO: Stanislas Veillet PhD
CSO: Rene Lafont
Chief Medical Officer: Susanna Del Signore
24 articles with Biophytis
Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for the treatment of aged related diseases, including neuromuscular diseases, today announced a €10 million capital increase through private placement. The capital increase will be
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
8/10/2020It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
8/6/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
7/6/2020Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
The amendment, which was filed with the FDA and AFMPS, proposes a reduction in the number of patients needed in SARA-INT based on fast deterioration of mobility seen in the SARA-OBS study in participants with sarcopenia
Achieved target number of 22 clinical sites opened and recruiting patients in the U.S. and Belgium. Filed protocol amendment with the regulatory agencies in both countries to optimize the SARA-INT Phase 2b clinical trial
Biophytis Opens 22nd Clinical Site in the SARA-INT Phase 2b Trial of Sarconeos (BIO101) for the Treatment of Sarcopenia
Target number of clinical sites reached, including leading hospitals and geriatric centers in the US and Europe Patient enrollment expected to complete in mid-2020
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
Biophytis Has FAMHP Approval to Conduct SARA-INT Phase IIb Interventional Study of Sarconeos in Sarcopenia in Belgium
The FAMHP approval will enable BIOPHYTIS to initiate the SARA-INT phase 2b interventional study in 3 clinical centers in Belgium.
BIOPHYTIS Completes a 7.5M Euro Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
Since July 1st, the Company has raised a total amount of €21 M.
BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
The approval will enable BIOPHYTIS to begin the SARA-INT interventional study in five clinical centers in the United States.
Operating income amounted to €(4,159) K as of June 30, 2017 compared to €(3,711) K as of June 30, 2016.
Biophytis Appoints Professor Thomas Voit to Scientific Advisory Board to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases
Professor Voit is the Director of the Biomedical Research Centre of the Great Ormond Street Hospital for Children NHS Foundation Trust and the Institute of Child Health, University College London.
Biophytis Completes A €10.4 Million Capital Increase To Finance Mid-Stage Clinical Trials For Two Novel Anti-Aging Drug-Candidates
Biophytis Filed IND Application For Approval By FDA Of SARA-INT Phase IIb Study Of Sarconeos In Sarcopenia
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy In Preclinical Models Of Duchenne Muscular Dystrophy